{
  "hash": "f21182ff4eb624f00801424940dc182c",
  "result": {
    "markdown": "---\ntitle: \"\"\ndate: last-modified\nexecute:   \n  freeze: auto  # re-render only when source changes\noutput: \n  rmarkdown::html_document:\n    highlight: pygments\n    number_sections: yes\n    self_contained: yes\n    toc: yes\n    toc_depth: 2\n    toc_float: yes\nformat: html\ntbl-colwidths: [7,20,30,10,23]\n---\n\n\n# Comprehensive list of talks\n\nA pdf file listing all my talks can be [downloaded](files/03_Kaspar_Rufibach_talks.pdf).\n\n# Talks for download\n\n::: {.panel-tabset .nav-pills}\n\n\n\n\n\n\n::: {.cell}\n\n:::\n\n## Invited talks {-} \n\n::: {.cell}\n::: {.cell-output-display}\n|Date       |Event                                                                                                           |Title                                                                                                                                                                                  |Material            |Comment                                                             |\n|:----------|:---------------------------------------------------------------------------------------------------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|:-------------------|:-------------------------------------------------------------------|\n|15.02.2024 |Effective Statistician Conference 2024                                                                          |Futility analyses - a strategic tool in drug development and not futile at all!                                                                                                        |[slides](files/talks/20240215_Rufibach_Futility.pdf)|                                                                    |\n|23.10.2023 |Italian Biostatistics Group (IBIG)                                                                              |Stop the abuse: A plea for a more principled approach to the analysis of time-to-event endpoints with competing risks, with a focus on analysis of AEs                                 |[slides](files/talks/20231023_Rufibach_IBIG_SAVVY.pdf)|                                                                    |\n|12.10.2023 |ASA/LUNGevity Foundation/FDA Statistical Forum                                                                  |Impact of Cross-over in the Evaluation of Overall Survival in cancer RCTs                                                                                                              |[slides](files/talks/20231012_Rufibach_Lungevity_crossover.pdf)|                                                                    |\n|18.09.2023 |CDDF workshop on \"innovative oncology clinical trial designs\", Amsterdam                                        |Estimands - industry perspective                                                                                                                                                       |[slides](files/talks/20230918_CDDF_Rufibach_Estimands.pdf)|                                                                    |\n|30.08.2023 |ISCB44 2023 Milan                                                                                               |Stop the abuse: A plea for a more principled approach to the analysis of time-to-event endpoints with competing risks, with a focus on analysis of Aes                                 |[slides](files/talks/20230828_Rufibach_SAVVY.pdf) &#124; [video](https://youtu.be/fUyXVkx12ak)|Short version of this talk, which starts at 58:20 of the recording. |\n|09.08.2023 |JSM 2023 Toronto                                                                                                |Assurance in drug development                                                                                                                                                          |[slides](files/talks/20230809_JSM23_Rufibach_Assurance.pdf)|                                                                    |\n|12.04.2023 |BBS seminar: Quantification of risk: ask the right questions or time to apply the estimand framework to safety! |Stop the abuse: A plea for a more principled approach to the analysis of time-to-event endpoints with varying follow-up times and/or competing risks, with a focus on analysis of AEs. |[slides](https://baselbiometrics.github.io/home/docs/events_past.html#quantification-of-risk-ask-the-right-questions-or-time-to-apply-the-estimand-framework-to-safety) &#124; [video](https://baselbiometrics.github.io/home/docs/events_past.html#quantification-of-risk-ask-the-right-questions-or-time-to-apply-the-estimand-framework-to-safety)|Long version of this talk, given at BBS seminar.                    |\n|08.08.2022 |JSM 2022 Washington DC<br>(virtual talk)                                                                        |MIRROS: Planning a Phase 3 Trial with Time-to-event Endpoint, a Cure Proportion, and a Futility Interim Analysis using Response                                                        |[slides](files/talks/20220808_Rufibach_MIRROS.pdf)|                                                                    |\n|22.02.2022 |University of Ulm                                                                                               |Efficient effect estimation in pre-specified subgroups in forest plots for a time-to-event endpoint                                                                                    |[slides](files/talks/20220222_Rufibach_subgroup.pdf)|                                                                    |\n|16.12.2021 |Royal Statistical Society Session on Design for Medical and Clinical studies                                    |Answering Old Questions with New Tools: Application of the ICH E9 Addendum in Oncology                                                                                                 |[slides](files/talks/20211216_Rufibach_complex_journeys.pdf)|                                                                    |\n|11.02.2021 |ASA/LUNGevity Foundation/FDA Statistical Forum                                                                  |How can the estimand framework support decentralized trials?                                                                                                                           |[slides](files/talks/20210211_DCTs_estimands.pdf)|                                                                    |\n|20.12.2020 |Vienna Biometric Section                                                                                        |Use of multistate models to improve decision-making in clinical trials                                                                                                                 |[slides](files/talks/20201220_Vienna_Rufibach_multistate.pdf)|                                                                    |\n|10.09.2018 |14th Basel Modeling & Simulation Seminar                                                                        |Immortal bias - you live longer if you cannot die!                                                                                                                                     |[slides](files/talks/20180910_Rufibach_immortal_bias.pdf)|                                                                    |\n|28.04.2016 |BBS spring seminar                                                                                              |Event projection: quantify uncertainty and manage expectations of broader teams                                                                                                        |[slides](https://baselbiometrics.github.io/home/docs/talks/20160428/1_Rufibach.pdf)|                                                                    |\n:::\n:::\n\n::: {.cell}\n\n:::\n\n## Contributed talks {-} \n\n::: {.cell}\n::: {.cell-output-display}\n|Date       |Event                                                                                               |Title                                                                                                                       |Material            |Comment               |\n|:----------|:---------------------------------------------------------------------------------------------------|:---------------------------------------------------------------------------------------------------------------------------|:-------------------|:---------------------|\n|28.08.2023 |ISCB44 2023 Milan /<br>CEN 2023 Basel                                                               |Clinical trial design based on a multistate model that jointly models progression-free and overall survival                 |[slides](files/talks/20230828_ISCB_Rufibach_PFS_OS.pdf) &#124; [video](https://youtu.be/GK-uu6Y_9B4)|Recording from Milan. |\n|22.08.2022 |ISCB43 2022 Newcastle                                                                               |Follow-up time in clinical trials with a time-to-event endpoint: Redefining the question(s)                                 |[slides](files/talks/20220822_ISCB43_Rufibach_FUquant.pdf)|                      |\n|16.06.2015 |Joint Meeting of the International Biometric Society Austro-Swiss and Italian Regions, Milan, Italy |Evaluation of possible designs for a three-arm clinical trial: Comparing a closed-testing design to potential alternatives. |[slides](files/talks/20150616_3arm_designs_ROeS_Milan.pdf)|                      |\n:::\n:::\n\n\n:::\n\n\n\n",
    "supporting": [],
    "filters": [
      "rmarkdown/pagebreak.lua"
    ],
    "includes": {},
    "engineDependencies": {},
    "preserve": {},
    "postProcess": true
  }
}